NCT07089641View on ClinicalTrials.gov

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2028

Conditions
IDH Wildtype GlioblastomaRecurrent AstrocytomaIDH Wildtype Recurrent GlioblastomaResectable AstrocytomaResectable Glioblastoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo urine, blood, and CSF sample collection

PROCEDURE

Echocardiography Test

Undergo ECHO

DRUG

EGFR Inhibitor ERAS-801

Given PO

OTHER

Fludeoxyglucose F-18

Given FDG

PROCEDURE

Magnetic Resonance Imaging

Undergo brain MRI

PROCEDURE

Positron Emission Tomography

Undergo FDG PET

PROCEDURE

Surgical Procedure

Undergo surgical resection

Trial Locations (1)

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER